906 related articles for article (PubMed ID: 24998118)
1. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.
Cooperberg MR; Davicioni E; Crisan A; Jenkins RB; Ghadessi M; Karnes RJ
Eur Urol; 2015 Feb; 67(2):326-33. PubMed ID: 24998118
[TBL] [Abstract][Full Text] [Related]
2. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
Ross AE; Johnson MH; Yousefi K; Davicioni E; Netto GJ; Marchionni L; Fedor HL; Glavaris S; Choeurng V; Buerki C; Erho N; Lam LL; Humphreys EB; Faraj S; Bezerra SM; Han M; Partin AW; Trock BJ; Schaeffer EM
Eur Urol; 2016 Jan; 69(1):157-65. PubMed ID: 26058959
[TBL] [Abstract][Full Text] [Related]
3. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
[TBL] [Abstract][Full Text] [Related]
4. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features.
Karnes RJ; Choeurng V; Ross AE; Schaeffer EM; Klein EA; Freedland SJ; Erho N; Yousefi K; Takhar M; Davicioni E; Cooperberg MR; Trock BJ
Eur Urol; 2018 Feb; 73(2):168-175. PubMed ID: 28400167
[TBL] [Abstract][Full Text] [Related]
5. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
6. Predicting survival of men with recurrent prostate cancer after radical prostatectomy.
Dell'Oglio P; Suardi N; Boorjian SA; Fossati N; Gandaglia G; Tian Z; Moschini M; Capitanio U; Karakiewicz PI; Montorsi F; Karnes RJ; Briganti A
Eur J Cancer; 2016 Feb; 54():27-34. PubMed ID: 26707594
[TBL] [Abstract][Full Text] [Related]
7. Survival following biochemical recurrence after radical prostatectomy and adjuvant radiotherapy in patients with prostate cancer: the impact of competing causes of mortality and patient stratification.
Abdollah F; Boorjian S; Cozzarini C; Suardi N; Sun M; Fiorino C; di Muzio N; Karakiewicz PI; Montorsi F; Karnes RJ; Briganti A
Eur Urol; 2013 Oct; 64(4):557-64. PubMed ID: 23506833
[TBL] [Abstract][Full Text] [Related]
8. Identifying the Most Informative Prediction Tool for Cancer-specific Mortality After Radical Prostatectomy: Comparative Analysis of Three Commonly Used Preoperative Prediction Models.
Boehm K; Larcher A; Beyer B; Tian Z; Tilki D; Steuber T; Karakiewicz PI; Heinzer H; Graefen M; Budäus L
Eur Urol; 2016 Jun; 69(6):1038-43. PubMed ID: 26272236
[TBL] [Abstract][Full Text] [Related]
9. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
[TBL] [Abstract][Full Text] [Related]
10. Validation of a genomic classifier for prediction of metastasis and prostate cancer-specific mortality in African-American men following radical prostatectomy in an equal access healthcare setting.
Howard LE; Zhang J; Fishbane N; Hoedt AM; Klaassen Z; Spratt DE; Vidal AC; Lin D; Hitchins MP; You S; Freeman MR; Yamoah K; Davicioni E; Freedland SJ
Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):419-428. PubMed ID: 31844180
[TBL] [Abstract][Full Text] [Related]
11. Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier.
Tosoian JJ; Birer SR; Jeffrey Karnes R; Zhang J; Davicioni E; Klein EE; Freedland SJ; Weinmann S; Trock BJ; Dess RT; Zhao SG; Jackson WC; Yamoah K; Dal Pra A; Mahal BA; Morgan TM; Mehra R; Kaffenberger S; Salami SS; Kane C; Pollack A; Den RB; Berlin A; Schaeffer EM; Nguyen PL; Feng FY; Spratt DE
Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):646-653. PubMed ID: 32231245
[TBL] [Abstract][Full Text] [Related]
12. Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy.
Punnen S; Freedland SJ; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Carroll PR; Cooperberg MR
Eur Urol; 2014 Jun; 65(6):1171-7. PubMed ID: 23587869
[TBL] [Abstract][Full Text] [Related]
13. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
[TBL] [Abstract][Full Text] [Related]
14. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.
Leapman MS; Nguyen HG; Cowan JE; Xue L; Stohr B; Simko J; Cooperberg MR; Carroll PR
Eur Urol; 2018 Nov; 74(5):668-675. PubMed ID: 30181067
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of biochemical recurrence-free survival after radical prostatectomy by cancer of the prostate risk assessment post-surgical (CAPRA-S) score.
Aktas BK; Ozden C; Bulut S; Tagci S; Erbay G; Gokkaya CS; Baykam MM; Memis A
Asian Pac J Cancer Prev; 2015; 16(6):2527-30. PubMed ID: 25824791
[TBL] [Abstract][Full Text] [Related]
16. Validation of a Genomic Classifier for Predicting Post-Prostatectomy Recurrence in a Community Based Health Care Setting.
Glass AG; Leo MC; Haddad Z; Yousefi K; du Plessis M; Chen C; Choeurng V; Abdollah F; Robbins B; Ra S; Richert-Boe KE; Buerki C; Pearson K; Davicioni E; Weinmann S
J Urol; 2016 Jun; 195(6):1748-53. PubMed ID: 26626216
[TBL] [Abstract][Full Text] [Related]
17. Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy.
Spratt DE; Dai DLY; Den RB; Troncoso P; Yousefi K; Ross AE; Schaeffer EM; Haddad Z; Davicioni E; Mehra R; Morgan TM; Rayford W; Abdollah F; Trabulsi E; Achim M; Tapia ELN; Guerrero M; Karnes RJ; Dicker AP; Hurwitz MA; Nguyen PL; Feng FFY; Freedland SJ; Davis JW
Eur Urol; 2018 Jul; 74(1):107-114. PubMed ID: 29233664
[TBL] [Abstract][Full Text] [Related]
18. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort.
Cooperberg MR; Simko JP; Cowan JE; Reid JE; Djalilvand A; Bhatnagar S; Gutin A; Lanchbury JS; Swanson GP; Stone S; Carroll PR
J Clin Oncol; 2013 Apr; 31(11):1428-34. PubMed ID: 23460710
[TBL] [Abstract][Full Text] [Related]
19. A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy.
Ross AE; Feng FY; Ghadessi M; Erho N; Crisan A; Buerki C; Sundi D; Mitra AP; Vergara IA; Thompson DJ; Triche TJ; Davicioni E; Bergstralh EJ; Jenkins RB; Karnes RJ; Schaeffer EM
Prostate Cancer Prostatic Dis; 2014 Mar; 17(1):64-9. PubMed ID: 24145624
[TBL] [Abstract][Full Text] [Related]
20. Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens.
Nguyen PL; Haddad Z; Ross AE; Martin NE; Deheshi S; Lam LLC; Chelliserry J; Tosoian JJ; Lotan TL; Spratt DE; Stoyanova RS; Punnen S; Ong K; Buerki C; Aranes M; Kolisnik T; Margrave J; Yousefi K; Choeurng V; Davicioni E; Trock BJ; Kane CJ; Pollack A; Davis JW; Feng FY; Klein EA
Eur Urol; 2017 Nov; 72(5):845-852. PubMed ID: 28528811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
